Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Eduardo Davila and Breelyn Wilky.

 
Connection Strength
 
 
 
1.185
 
  1. Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. Correction: A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2026 Jul 17; 32(14):3102.
    View in: PubMed
    Score: 0.249
  2. Magno JC, Guo J, Hall SC, Liu J, Albert GK, Carter JD, Davalos AS, Cao P, Bangar A, Drigot Z, Hudson H, Geluck T, Nevala WK, Markovic SN, Wilky BA, Davila E. Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer Res. 2026 Jun 01; 86(11):2688-2702.
    View in: PubMed
    Score: 0.246
  3. Geng D, Chen J, Sanchez A, Davalos SA, Wilcox P, Gonzales-Rivera D, Couts K, Tobin R, Robinson W, Nielsen AJ, Guo J, McCarter M, Crump L, Tsujimoto K, Wilky BA, Davila E. Melanoma leverages innate immune IRAK-M signaling to limit metastasis through PTPN22-Induced signaling repression. Cancer Lett. 2026 Feb 28; 639:218172.
    View in: PubMed
    Score: 0.238
  4. Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956.
    View in: PubMed
    Score: 0.232
  5. Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, Geng D, Bradeen X, Hintzsche JD, Robinson W, McCarter M, Amato C, Tobin R, Couts K, Wilky BA, Davila E. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024 10 22; 134(24).
    View in: PubMed
    Score: 0.220
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)